NL-OMON54356招募中2 期
FIGO 2018 stage IB2 (>2cm - <=4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F) - CONTESSA/NEOCO
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients must have histologically confirmed invasive cervical cancer with
- •adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring
- •>2 cm - <=4 cm
- •Patients must be >=18 years of age, and < 40 years of age
- •Patients must be premenopausal and wish to preserve fertility
- •no prior therapy to treat their cancer lesion, patients with diagnostic cone or
- •LEEP are allowed but a measurable tumor of >2 cm - <=4 cm is mandatory
- •Eastern Cooperative Group (ECOG) performance status <= 2
- •Within 7 days of the proposed start of treatment, patients must have normal
- •organ and marrow function
- •No evidence of active uncontrolled infection
- •Patient must have disease that is measurable per RECIST 1.1.
- •Ability to understand and willing to sign a written informed consent document.
- •A negative serum pregnancy test
排除标准
- •Patients who are receiving any other investigational agents.
- •Patients with other cancers requiring ongoing treatment.
- •Patients with known / evidence of brain metastases
- •Uncontrolled inter-current illness
- •Patients who are pregnant or breastfeeding
研究者
相似试验
招募中
1 期
FIGO 2018 stage IB2 (>2 cm - =4 cm ) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F)Cervical cancerCTIS2023-507230-24-00niversity Health Network95
进行中（未招募）
2 期
IBCSG 24-02 / BIG 2-02: Suppression of Ovarian Function TrialAdjuvant Breast CancerCancer - BreastACTRN12605000416695Breast Cancer Trials3,066
已完成
不适用
Early External Cephalic Version (ECV) 2 trialPregnancies with a foetus in breech presentationPregnancy and ChildbirthISRCTN56498577McMaster University Medical Centre (Canada)1,460
进行中（未招募）
1 期
An early phase clinical trial testing a new antibody (BI-1206) for use with rituximab in patients with slow-growing types of Non-Hodgkin Lymphoma that has not responded to or has returned after previous treatment with rituximabIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2018-000444-26-PLBioInvent International AB52
进行中（未招募）
1 期
An early phase clinical trial testing a new antibody (BI-1206) for use with rituximab in patients with slow-growing types of Non-Hodgkin Lymphoma that has not responded to or has returned after previous treatment with rituximabIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2018-000444-26-ESBioInvent International AB30